Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.

EH, Choy; DA, Isenberg; T, Garrood; S, Farrow; Y, Ioannou; H, Bird; N, Cheung; B, Williams; B, Hazleman; R, Price; K, Yoshizaki; N, Nishimoto; T, Kishimoto; GS, Panayi

doi:10.1002/art.10623

Public

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.

Shared by NobleBlocks on Dec 1, 2002 • 12:00 AM UTC

Authors:

Choy EH

Isenberg DA

Garrood T

Abstract

Objective To investigate the safety and efficacy of MRA, a recombinant human anti-interleukin-6 (anti-IL-6) receptor monoclonal antibody of the IgG1 subclass that inhibits the function of IL-6, in patients with established rheumatoid arthritis (RA).Methods A randomized, double-blind, placebo-control...

Discussions